Cargando…

Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview

Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Eatmann, Ahmed Ismail, Hamouda, Esraa, Hamouda, Heba, Farouk, Hossam Khaled, Jobran, Afnan W. M., Omar, Abdallah A., Madeeh, Alyaa Khaled, Al-dardery, Nada Mostafa, Elnoamany, Salma, Abd-Elnasser, Eman Gamal, Koraiem, Abdullah Muhammed, Ahmed, Alhassan Ali, Abouzid, Mohamed, Karaźniewicz-Łada, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146416/
https://www.ncbi.nlm.nih.gov/pubmed/37110201
http://dx.doi.org/10.3390/metabo13040543
_version_ 1785034576010149888
author Eatmann, Ahmed Ismail
Hamouda, Esraa
Hamouda, Heba
Farouk, Hossam Khaled
Jobran, Afnan W. M.
Omar, Abdallah A.
Madeeh, Alyaa Khaled
Al-dardery, Nada Mostafa
Elnoamany, Salma
Abd-Elnasser, Eman Gamal
Koraiem, Abdullah Muhammed
Ahmed, Alhassan Ali
Abouzid, Mohamed
Karaźniewicz-Łada, Marta
author_facet Eatmann, Ahmed Ismail
Hamouda, Esraa
Hamouda, Heba
Farouk, Hossam Khaled
Jobran, Afnan W. M.
Omar, Abdallah A.
Madeeh, Alyaa Khaled
Al-dardery, Nada Mostafa
Elnoamany, Salma
Abd-Elnasser, Eman Gamal
Koraiem, Abdullah Muhammed
Ahmed, Alhassan Ali
Abouzid, Mohamed
Karaźniewicz-Łada, Marta
author_sort Eatmann, Ahmed Ismail
collection PubMed
description Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. This study is a comprehensive review that highlights the potential benefits of using thalidomide, in combination with other medications, to treat glioblastoma and its associated inflammatory conditions. Additionally, the review examines the mechanism of action of thalidomide in different types of tumors, which may be beneficial in treating glioblastoma. To our knowledge, a similar study has not been conducted. We found that thalidomide, when used in combination with other medications, has been shown to produce better outcomes in several conditions or symptoms, such as myelodysplastic syndromes, multiple myeloma, Crohn’s disease, colorectal cancer, renal failure carcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma. However, challenges may persist for newly diagnosed or previously treated patients, with moderate side effects being reported, particularly with the various mechanisms of action observed for thalidomide. Therefore, thalidomide, used alone, may not receive significant attention for use in treating glioblastoma in the future. Conducting further research by replicating current studies that show improved outcomes when thalidomide is combined with other medications, using larger sample sizes, different demographic groups and ethnicities, and implementing enhanced therapeutic protocol management, may benefit these patients. A meta-analysis of the combinations of thalidomide with other medications in treating glioblastoma is also needed to investigate its potential benefits further.
format Online
Article
Text
id pubmed-10146416
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101464162023-04-29 Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview Eatmann, Ahmed Ismail Hamouda, Esraa Hamouda, Heba Farouk, Hossam Khaled Jobran, Afnan W. M. Omar, Abdallah A. Madeeh, Alyaa Khaled Al-dardery, Nada Mostafa Elnoamany, Salma Abd-Elnasser, Eman Gamal Koraiem, Abdullah Muhammed Ahmed, Alhassan Ali Abouzid, Mohamed Karaźniewicz-Łada, Marta Metabolites Review Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. This study is a comprehensive review that highlights the potential benefits of using thalidomide, in combination with other medications, to treat glioblastoma and its associated inflammatory conditions. Additionally, the review examines the mechanism of action of thalidomide in different types of tumors, which may be beneficial in treating glioblastoma. To our knowledge, a similar study has not been conducted. We found that thalidomide, when used in combination with other medications, has been shown to produce better outcomes in several conditions or symptoms, such as myelodysplastic syndromes, multiple myeloma, Crohn’s disease, colorectal cancer, renal failure carcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma. However, challenges may persist for newly diagnosed or previously treated patients, with moderate side effects being reported, particularly with the various mechanisms of action observed for thalidomide. Therefore, thalidomide, used alone, may not receive significant attention for use in treating glioblastoma in the future. Conducting further research by replicating current studies that show improved outcomes when thalidomide is combined with other medications, using larger sample sizes, different demographic groups and ethnicities, and implementing enhanced therapeutic protocol management, may benefit these patients. A meta-analysis of the combinations of thalidomide with other medications in treating glioblastoma is also needed to investigate its potential benefits further. MDPI 2023-04-11 /pmc/articles/PMC10146416/ /pubmed/37110201 http://dx.doi.org/10.3390/metabo13040543 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Eatmann, Ahmed Ismail
Hamouda, Esraa
Hamouda, Heba
Farouk, Hossam Khaled
Jobran, Afnan W. M.
Omar, Abdallah A.
Madeeh, Alyaa Khaled
Al-dardery, Nada Mostafa
Elnoamany, Salma
Abd-Elnasser, Eman Gamal
Koraiem, Abdullah Muhammed
Ahmed, Alhassan Ali
Abouzid, Mohamed
Karaźniewicz-Łada, Marta
Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview
title Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview
title_full Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview
title_fullStr Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview
title_full_unstemmed Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview
title_short Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview
title_sort potential use of thalidomide in glioblastoma treatment: an updated brief overview
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146416/
https://www.ncbi.nlm.nih.gov/pubmed/37110201
http://dx.doi.org/10.3390/metabo13040543
work_keys_str_mv AT eatmannahmedismail potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT hamoudaesraa potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT hamoudaheba potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT faroukhossamkhaled potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT jobranafnanwm potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT omarabdallaha potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT madeehalyaakhaled potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT aldarderynadamostafa potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT elnoamanysalma potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT abdelnasseremangamal potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT koraiemabdullahmuhammed potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT ahmedalhassanali potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT abouzidmohamed potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview
AT karazniewiczładamarta potentialuseofthalidomideinglioblastomatreatmentanupdatedbriefoverview